NCT06289998View on ClinicalTrials.gov

Study of Tamibarotene in Patients With ADPKD

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

December 22, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Interventions
DRUG

Tamibarotene

Subjects are administrated to tamibarotene 4 mg in daily for 52 weeks.

DRUG

Placebo

Subjects are administrated to placebo in daily for 52 weeks.

Trial Locations (8)

830-0011

Kurume University Hospital, Kurume

060-8648

Hokkaido University Hospital, Sapporo

247-8533

Shonan Kamakura General Hospital, Kamakura

213-8587

Toranomon Hospital Kajigaya, Kawasaki

606-8507

Kyoto University Hospital, Kyoto

113-8431

Juntendo University School of Medicine Juntendo Hospital, Bunkyo-ku

105-8470

Toranomon Hospital, Minato-ku

162-8666

Tokyo Women's Medical University Hospital, Shinjukuku

All Listed Sponsors
lead

Rege Nephro Co., Ltd.

INDUSTRY